vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and MIMEDX GROUP, INC. (MDXG). Click either name above to swap in a different company.

MIMEDX GROUP, INC. is the larger business by last-quarter revenue ($118.1M vs $71.0M, roughly 1.7× Cheer Holding, Inc.). MIMEDX GROUP, INC. runs the higher net margin — 12.9% vs 10.9%, a 1.9% gap on every dollar of revenue. On growth, MIMEDX GROUP, INC. posted the faster year-over-year revenue change (27.1% vs -0.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.

CHR vs MDXG — Head-to-Head

Bigger by revenue
MDXG
MDXG
1.7× larger
MDXG
$118.1M
$71.0M
CHR
Growing faster (revenue YoY)
MDXG
MDXG
+27.2% gap
MDXG
27.1%
-0.1%
CHR
Higher net margin
MDXG
MDXG
1.9% more per $
MDXG
12.9%
10.9%
CHR

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CHR
CHR
MDXG
MDXG
Revenue
$71.0M
$118.1M
Net Profit
$7.8M
$15.2M
Gross Margin
70.7%
83.9%
Operating Margin
11.7%
17.8%
Net Margin
10.9%
12.9%
Revenue YoY
-0.1%
27.1%
Net Profit YoY
-37.5%
104.2%
EPS (diluted)
$0.67
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
MDXG
MDXG
Q4 25
$118.1M
Q3 25
$113.7M
Q2 25
$71.0M
$98.6M
Q1 25
$88.2M
Q4 24
$92.9M
Q3 24
$84.1M
Q2 24
$71.1M
$87.2M
Q1 24
$84.7M
Net Profit
CHR
CHR
MDXG
MDXG
Q4 25
$15.2M
Q3 25
$16.7M
Q2 25
$7.8M
$9.6M
Q1 25
$7.0M
Q4 24
$7.4M
Q3 24
$8.1M
Q2 24
$12.4M
$17.6M
Q1 24
$9.3M
Gross Margin
CHR
CHR
MDXG
MDXG
Q4 25
83.9%
Q3 25
83.5%
Q2 25
70.7%
81.1%
Q1 25
81.2%
Q4 24
81.8%
Q3 24
81.8%
Q2 24
73.4%
83.0%
Q1 24
84.7%
Operating Margin
CHR
CHR
MDXG
MDXG
Q4 25
17.8%
Q3 25
19.5%
Q2 25
11.7%
12.5%
Q1 25
9.4%
Q4 24
11.9%
Q3 24
13.3%
Q2 24
16.4%
26.9%
Q1 24
15.6%
Net Margin
CHR
CHR
MDXG
MDXG
Q4 25
12.9%
Q3 25
14.7%
Q2 25
10.9%
9.8%
Q1 25
8.0%
Q4 24
8.0%
Q3 24
9.6%
Q2 24
17.5%
20.2%
Q1 24
10.9%
EPS (diluted)
CHR
CHR
MDXG
MDXG
Q4 25
$0.10
Q3 25
$0.11
Q2 25
$0.67
$0.06
Q1 25
$0.05
Q4 24
$0.05
Q3 24
$0.05
Q2 24
$1.23
$0.12
Q1 24
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
MDXG
MDXG
Cash + ST InvestmentsLiquidity on hand
$166.1M
Total DebtLower is stronger
$18.0M
Stockholders' EquityBook value
$322.1M
$256.5M
Total Assets
$362.7M
$342.7M
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
MDXG
MDXG
Q4 25
$166.1M
Q3 25
$142.1M
Q2 25
$118.9M
Q1 25
$106.4M
Q4 24
$104.4M
Q3 24
$88.8M
Q2 24
$186.1M
$69.0M
Q1 24
$48.5M
Total Debt
CHR
CHR
MDXG
MDXG
Q4 25
$18.0M
Q3 25
Q2 25
Q1 25
Q4 24
$19.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CHR
CHR
MDXG
MDXG
Q4 25
$256.5M
Q3 25
$238.9M
Q2 25
$322.1M
$216.6M
Q1 25
$202.8M
Q4 24
$193.1M
Q3 24
$181.0M
Q2 24
$286.1M
$168.0M
Q1 24
$155.7M
Total Assets
CHR
CHR
MDXG
MDXG
Q4 25
$342.7M
Q3 25
$319.0M
Q2 25
$362.7M
$291.1M
Q1 25
$270.4M
Q4 24
$263.9M
Q3 24
$243.9M
Q2 24
$333.2M
$230.2M
Q1 24
$221.7M
Debt / Equity
CHR
CHR
MDXG
MDXG
Q4 25
0.07×
Q3 25
Q2 25
Q1 25
Q4 24
0.10×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
MDXG
MDXG
Operating Cash FlowLast quarter
$3.9M
$25.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.51×
1.64×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
MDXG
MDXG
Q4 25
$25.0M
Q3 25
$29.3M
Q2 25
$3.9M
$14.4M
Q1 25
$5.3M
Q4 24
$18.8M
Q3 24
$19.6M
Q2 24
$-6.7M
$21.8M
Q1 24
$6.0M
Cash Conversion
CHR
CHR
MDXG
MDXG
Q4 25
1.64×
Q3 25
1.75×
Q2 25
0.51×
1.50×
Q1 25
0.75×
Q4 24
2.53×
Q3 24
2.42×
Q2 24
-0.54×
1.24×
Q1 24
0.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHR
CHR

Segment breakdown not available.

MDXG
MDXG

Wound$78.7M67%
Surgical$39.4M33%

Related Comparisons